PAGE 1 OF 4 PAGES
Amendment No. 50

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a licensee is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

	License	ee	In accordance with letter dated September 22, 2017.	4. Expiration Date: November 30, 2023	
Porter Regional Hospital			LEAR REGULA	5. Docket No.: 030-12150	
. 85 East U.S. F Valparaiso, IN	•		3. License number: 13-17073-01 is amended in its entirety to read as follows:	Reference No.:	
Byproduct, source and/or special nu material		7. Chemical and/or physic	8. Maximum amount that lice may possess at any one til under this license		
Any byproduct permitted by 10 35.100		A. Any O	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CF 35.100.	
 Any byproduct permitted by 10 35.200 		3. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200	
2. Any byproduct permitted by 10 35.300		C. Any	C. 2 curies total	C. For any use permitted by 10 CFR 35.300.	
D. Iridium-192 pe 10 CFR 35.400		D. Sealed Sources (Bes International, Inc., Mo		 For any manual brachytherapy procedure permitted by 10 CFR 35.4 	
E. lodine-125 per 10 CFR 35.400		E. Sealed Sources (Bar Brachytherapy, Inc, M 1251)		E. For any manual brachytherapy procedure permitted by 10 CFR 35.4	

NRC FORM 374A		U.S. NUCLEAR I	REGULATORY COMMI	SSION	PAGE 2 OF 4 PAGES			
MATERIALS LICENSE		License Number 13-17073-01		Docket or Reference 030-12150	e Number			
SUPPLEMENTARY SHE		Amendment No. 50	,					
Byproduct, source, and/or special nuclear material	Chemical and	or physical form		at any one time	9. Authorized use			
10 CFR 35.1000	Technology (s (SIR-Spheres AEA QSA , Model Sirtex ted SIR ₁ Spheres)	F. 2 curies total	A TOP	F. For medical use as permitted by 10 CFR 35.1000 in a Sirtex Medical Limited brachytherapy afterloader delivery system.			
B. Licensed material in Subi Chesterton, Indiana and a 11. The Radiation Safety Officer 12. Licensed material shall only b A. Individuals permitted to w	CONDITIONS Licensed material may be used or stored at the licensee's facilities located at 85 East U.S. Highway 6, Valparaiso, Indiana. Licensed material in Subitem Nos. 6.A. and 6.B. may be used or stored at the licensee's facilities located at 1505 South Calumet, Chesterton, Indiana and at Porter Physician Services: LLC d/b/a Porter Physician Group; 2000 Roosevelt Road, Valparaiso, Indiana. Re Radiation Safety Officer (RSO) for this license is James M. Forde, M.D. Sensed material shall only be used by, or under the supervision of: Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14. The following individuals are authorized users for the material and medical uses as indicated:							
B. The following individuals	are autnoriz	ed users for the materi	ai and medical us	es as indicated:				
Authorized User(M.D.,D.0	O.,etc.)	Material and Use			,			
Koppolu P. Sarma, M.D.		10 CFR 35.400						
Esther Lee, M.D.		10 CFR 35.100, 35	.200 and 35.300 ((limited to the oral	l administration of sodium iodide I-131)			
Michael Wheat, M.D.		10 CFR 35.200						
Keith Atassi M.D.		10 CFR 35.200						

NRC FORM 374A	U.S. NUCLEAR REGULATORY	COMMISSION	PAGE 3 OF 4 PAGES
MATERIALS LICENSE	License Number 13-17073-01	Docket or Reference Number 030-12150	
SUPPLEMENTARY SHEET	Amendment No. 50		
Authorized User(M.D.,D.O.,etc.)	Material and Use		
John A. Forchetti, M.D.	10 CFR 35.100 and 35.200		
Hector J. Marchand, M.D.	10 CFR 35.200 R REG/	11	
Vivek Mishra, M.D.		(limited to the oral administration of beta-emitter, or photon-emitting ra	
Anil Kothari, M.D.	energy less than 150 keV) and	35.1000 (limited to yttrium-90 as S 300 (limited to the oral administrat	IR-Spheres)
Jeffrey M. Huth, M.D.	10 CFR 35.100 and 35.200		
Maximo V. Bleza, D.O.	10 CFR 35.100, 35.200 and 35.	300	
James M. Forde, M.D.	10 CFR 35.100, 35.200 and 35.	300	
Sandeep Sehgal, M.D.	10 CFR 35.200	C 2000	
Jeffrey Jon Quackenbush, M.D.	10 CFR 35.300 and 35.400	S	
Amjad Alkadri, M.D.	10 CFR 35.100, 35.200, 35.300	**************************************	
Omar Barakat, M.D.		300 (limited to the oral administrat any beta-emitter, or photon-emittir 35.1000 (limited to yttrium-90 as S	ng radionuclide with a photon
Jay D. Shah, M.D.	10 CFR 35.100 and 35.200	55. 1000 kg/med to yttham=50 as 0	int-ophicies)
Steven L. Hossler, M.D.	10 CFR 35 00 and 35,200	Z -	
Akram Kholoki, M.D.	10 CFR 35.100 and 35.200		

- 13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application dated June 21, 2013 (ML13183A468)
 - B. Letter dated August 4, 2015 (ML15224B609)
 - C. Letter dated September 22, 2017 (ML17268A220)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Bv:

Colleen Carol Casey

Region 3

Date: January 16, 2018